Taletrectinib free base

Synonyms: DS-6051b free base; AB-106 free base; IBI-344 free base
Taletrectinib (DS-6051b) free base 是一种有效的口服活性下一代选择性 ROS1/NTRK 抑制剂,对重组 ROS1、NTRK1、NTRK2 和 NTRK3 的 IC50 分别为 0.207、0.622、2.28 和 0.98 nM,同时还能抑制 ROS1 G2032R 及其他抗 Crizotinib 的 ROS1 突变体。
产品编号: MS-H47695 CAS No.: 1505514-27-1 分子式: C23H24FN5O 分子量: 405.47
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Taletrectinib (DS-6051b) free base 是一种有效的口服活性下一代选择性 ROS1/NTRK 抑制剂,对重组 ROS1、NTRK1、NTRK2 和 NTRK3 的 IC50 分别为 0.207、0.622、2.28 和 0.98 nM,同时还能抑制 ROS1 G2032R 及其他抗 Crizotinib 的 ROS1 突变体。

生物实验数据

生物活性 Taletrectinib (DS-6051b) free base is a potent, orally active, next-generation selective ROS1/NTRK inhibitor that inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50 values of 0.207, 0.622, 2.28, and 0.98 nM, respectively, and also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants.
体外研究
(In Vitro)

The IC50 of Taletrectinib free base (1-1000 nM; 72 hours) against Ba/F3-TPM3-NTRK1, Ba/F3-ETV6-NTRK1, -NTRK2, -NTRK3, or KM12 cells is ~3-20 nM.
Taletrectinib free base (0.001-1000 nM; 2 hours) dose dependently inhibited autophosphorylation of ROS1 in U-118-MG cells in vitro.
Taletrectinib (DS-6051b) free base potently inhibits autophosphorylation of ROS1 in JFCR-165, JFCR-168, and MGH193-1B cells.
Taletrectinib free base partially suppresses phospho-NTRK1 at 10 nM, and completely suppresses by 100 nM. Taletrectinib free base potently inhibits recombinant ROS1, NTRK1, and NTRK3 in sub-nanomolar concentration in an ATP-competitive manner. Taletrectinib free base almost completely inhibits ACK, ALK, DDR1, and LTK at 0.2 μM among 160 kinases in the presence of 1 mM ATP, but did not inhibit other 152 kinases strongly.
Taletrectinib free base effectively inhibits Crizotinib-resistant ROS1 secondary mutations, including G2032R solvent front mutation.

Cell Viability Assay

Cell Line: TPM3-NTRK1-induced Ba/F3 cells, KM12 cells
Concentration: 1-1000 nM
Incubation Time: 72 hours
Result: Inhibited TPM3-NTRK1-induced Ba/F3 cells and KM12 cells viability.

Western Blot Analysis

Cell Line: U-118 MG cells (harboring FIG-ROS1 fusion gene)
Concentration: 0.001-1000 nM
Incubation Time: 2 hours
Result: Dose dependently inhibited autophosphorylation of ROS1 in U-118-MG cells.
体内研究
(In Vivo)

Taletrectinib (DS-6051b) free base (25-200 mg/kg; p.o.; once daily for 18 days) shows antitumor activity.
Taletrectinib free base (6.25-200 mg/kg; p.o.; once daily for 8 days) inhibits NTRK-rearranged cancer in Balb-c nu/nu mice bearing KM12 cells.
Taletrectinib free base (3-100 mg/kg; p.o.; once daily for 4 days) shows rapid tumor regression in the wild-type (WT) and the G2032R-mutant Ba/F3-bearing mice without severe body weight loss.

Animal Model: Balb-c nu/nu mice (bearing U-118 MG cells)
Dosage: 25, 50, 100, and 200 mg/kg
Administration: P.o.; once daily for 18 days
Result: Effectively inhibited tumor growth at ≥25 mg/kg without significant body weight loss.

化学信息

分子量 405.47
分子式 C23H24FN5O
CAS No. 1505514-27-1
别名 DS-6051b free base; AB-106 free base; IBI-344 free base

储存&溶解度

溶解度信息
DMSO: 150 mg/mL (369.94 mM), Sonication is recommended.
体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (24.66 mM), Solution.
10% DMSO+90% Saline: < 10 mg/mL (24.66 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础